GENEURO SA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.465 EUR | +0.34% |
|
+0.34% | +34.40% |
| Mar. 20 | Geneuro SA Announces Appointments of Board of Directors | CI |
| Feb. 02 | GeNeuro: share price falls after private placement | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2023 * | - | Sales 2024 * | 28.2M 30.34M | Capitalization | 43.21M 46.49M |
|---|---|---|---|---|---|
| Net income 2023 * | -11M -11.83M | Net income 2024 * | 1M 1.08M | EV / Sales 2023 * | - |
| Net Debt 2023 * | 13M 13.99M | Net Debt 2024 * | 7.9M 8.5M | EV / Sales 2024 * | 1.81 x |
| P/E ratio 2023 * |
-3.4
x | P/E ratio 2024 * |
48.7
x | Employees | 19 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 73.47% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.01% | ||
| 1 week | -0.34% | ||
| 1 month | -1.35% | ||
| 3 months | +30.36% | ||
| 6 months | +23.73% | ||
| Current year | +33.94% |
1 week
1.42
1.51
1 month
1.401.53
Current year
1.051.70
1 year
0.941.99
3 years
0.944.39
5 years
0.946.28
10 years
0.9413.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 05-12-31 | |
Hervé Perron
FOU | Founder | 66 | 05-12-31 |
Miguel Payró
DFI | Director of Finance/CFO | 62 | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-05-26 | |
Michel Dubois
BRD | Director/Board Member | 81 | 08-07-15 |
Gordon Francis
BRD | Director/Board Member | 75 | 15-03-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 1.465 | +0.34% | 7 249 |
| 24-05-06 | 1.46 | -2.01% | 8,717 |
| 24-05-03 | 1.49 | +3.47% | 6,956 |
| 24-05-02 | 1.44 | -1.37% | 6,017 |
| 24-04-30 | 1.46 | -0.34% | 6,700 |
Real-time Euronext Paris, May 06, 2024 at 09:06 am EDT
More quotes
GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Calendar
2024-09-29
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.46
EUR
Average target price
4
EUR
Spread / Average Target
+173.97%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +33.94% | 46.56M | |
| +22.81% | 46.81B | |
| +46.56% | 41.29B | |
| -1.88% | 41.37B | |
| -6.20% | 28.87B | |
| +11.33% | 26.06B | |
| -21.00% | 19.13B | |
| -1.43% | 11.96B | |
| +30.73% | 12.39B | |
| -0.48% | 12.08B |
- Stock Market
- Equities
- GNRO Stock